Details for New Drug Application (NDA): 020803
✉ Email this page to a colleague
The generic ingredient in ALREX is loteprednol etabonate. There are ten drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.
Summary for 020803
Tradename: | ALREX |
Applicant: | Bausch And Lomb |
Ingredient: | loteprednol etabonate |
Patents: | 0 |
Pharmacology for NDA: 020803
Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Medical Subject Heading (MeSH) Categories for 020803
Suppliers and Packaging for NDA: 020803
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
ALREX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020803 | NDA | Bausch & Lomb Incorporated | 24208-353 | 24208-353-01 | 1 BOTTLE, DROPPER in 1 CARTON (24208-353-01) / 1 mL in 1 BOTTLE, DROPPER |
ALREX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020803 | NDA | Bausch & Lomb Incorporated | 24208-353 | 24208-353-05 | 1 BOTTLE, DROPPER in 1 CARTON (24208-353-05) / 5 mL in 1 BOTTLE, DROPPER |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SUSPENSION/DROPS;OPHTHALMIC | Strength | 0.2% | ||||
Approval Date: | Mar 9, 1998 | TE: | AB | RLD: | Yes |
Expired US Patents for NDA 020803
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bausch And Lomb | ALREX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020803-001 | Mar 9, 1998 | ⤷ Sign Up | ⤷ Sign Up |
Bausch And Lomb | ALREX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020803-001 | Mar 9, 1998 | ⤷ Sign Up | ⤷ Sign Up |
Bausch And Lomb | ALREX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020803-001 | Mar 9, 1998 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription